Publicaciones en colaboración con investigadores/as de Pitié-Salpêtrière Hospital (21)

2023

  1. Diagnostics in Waldenström’s macroglobulinemia: a consensus statement of the European Consortium for Waldenström’s Macroglobulinemia

    Leukemia, Vol. 37, Núm. 2, pp. 388-395

  2. Plain Language Summary of the iNNOVATE study: ibrutinib plus rituximab is well-tolerated and effective in people with Waldenström's macroglobulinemia

    Future Oncology, Vol. 19, Núm. 5, pp. 345-353

  3. Report of Consensus Panel 3 from the 11th International workshop on Waldenström's Macroglobulinemia: Recommendations for molecular diagnosis in Waldenström's Macroglobulinemia

    Seminars in Hematology

  4. Report of consensus panel 1 from the 11th International Workshop on Waldenstrom's Macroglobulinemia on management of symptomatic, treatment-naïve patients

    Seminars in Hematology

  5. Report of consensus panel 2 from the 11th international workshop on Waldenström's macroglobulinemia on the management of relapsed or refractory WM patients

    Seminars in Hematology

  6. Report of consensus panel 5 from the 11th international workshop on Waldenstrom's macroglobulinemia on COVID-19 prophylaxis and management

    Seminars in Hematology

  7. Report of consensus panel 7 from the 11th international workshop on Waldenström macroglobulinemia on priorities for novel clinical trials

    Seminars in Hematology

  8. SARS-CoV-2 Infection in Patients with Waldenstrom's Macroglobulinemia: A Multicenter International Cohort Study

    HemaSphere

  9. Zanubrutinib Versus Ibrutinib in Symptomatic Waldenström Macroglobulinemia: Final Analysis From the Randomized Phase III ASPEN Study

    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, Vol. 41, Núm. 33, pp. 5099-5106

2021

  1. Validation of the EuroClonality-NGS DNA capture panel as an integrated genomic tool for lymphoproliferative disorders

    Blood Advances, Vol. 5, Núm. 16, pp. 3188-3198

2020

  1. A prognostic index predicting survival in transformed Waldenström macroglobulinemia

    Haematologica, Vol. Online ahead of print

2019

  1. Quality control and quantification in IG/TR next-generation sequencing marker identification: protocols and bioinformatic functionalities by EuroClonality-NGS

    Leukemia, Vol. 33, Núm. 9, pp. 2254-2265

  2. Standardized next-generation sequencing of immunoglobulin and T-cell receptor gene recombinations for MRD marker identification in acute lymphoblastic leukaemia; a EuroClonality-NGS validation study

    Leukemia, Vol. 33, Núm. 9, pp. 2241-2253

2017

  1. High-dose therapy and autologous stem cell transplantation in patients with poems syndrome: A retrospective study of the plasma cell disorder sub-committee of the chronic malignancy working party of the European society for blood & marrow transplantation

    Haematologica, Vol. 102, Núm. 1, pp. 160-167

  2. Ibrutinib for patients with rituximab-refractory Waldenström's macroglobulinaemia (iNNOVATE): an open-label substudy of an international, multicentre, phase 3 trial

    The Lancet Oncology, Vol. 18, Núm. 2, pp. 241-250

2013

  1. Response assessment in Waldenström macroglobulinaemia: Update from the VIth International Workshop

    British Journal of Haematology, Vol. 160, Núm. 2, pp. 171-176

2012

  1. EuroClonality/BIOMED-2 guidelines for interpretation and reporting of Ig/TCR clonality testing in suspected lymphoproliferations

    Leukemia, Vol. 26, Núm. 10, pp. 2159-2171

2007

  1. Improved reliability of lymphoma diagnostics via PCR-based clonality testing: - Report of the BIOMED-2 Concerted Action BHM4-CT98-3936

    Leukemia, Vol. 21, Núm. 2, pp. 201-206

  2. Powerful strategy for polymerase chain reaction-based clonality assessment in T-cell malignancies Report of the BIOMED-2 Concerted Action BHM4 CT98-3936

    Leukemia, Vol. 21, Núm. 2, pp. 215-221

2006

  1. Update on recommendations for assessing response from the Third International Workshop on Waldenström's macroglobulinemia

    Clinical Lymphoma and Myeloma, Vol. 6, Núm. 5, pp. 380-383